Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2012 1
2022 2
2023 2
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP): Results of a Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial.
Pignolo RJ, Baujat G, Hsiao EC, Keen R, Wilson A, Packman J, Strahs AL, Grogan DR, Kaplan FS. Pignolo RJ, et al. J Bone Miner Res. 2022 Oct;37(10):1891-1902. doi: 10.1002/jbmr.4655. Epub 2022 Aug 17. J Bone Miner Res. 2022. PMID: 35854638 Free PMC article. Clinical Trial.
Patients experiencing a flare-up were enrolled in two cohorts: (1) patients 15 years were randomized 3:1 to palovarotene 10/5 mg (weeks 1-2/3-6) or placebo; (2) patients 6 years were randomized 3:3:2 to palovarotene 10/5 mg, palovarotene 5/2.5 mg (weeks 1-2/3 …
Patients experiencing a flare-up were enrolled in two cohorts: (1) patients 15 years were randomized 3:1 to palovarotene 10/5 mg (wee …
A Pharmacokinetic, Safety, and Tolerability Trial of Palovarotene in Healthy Japanese and Non-Japanese Participants.
Dube L, Haga N, Grogan D, Ogier J, Le Quan Sang KH. Dube L, et al. Eur J Drug Metab Pharmacokinet. 2023 Mar;48(2):141-150. doi: 10.1007/s13318-023-00815-x. Epub 2023 Feb 18. Eur J Drug Metab Pharmacokinet. 2023. PMID: 36802022 Free PMC article. Clinical Trial.
BACKGROUND AND OBJECTIVE: Palovarotene is an oral, selective retinoic acid receptor gamma agonist under investigation for fibrodysplasia ossificans progressiva (FOP). ...Mean plasma concentration-time profiles were similar between the two cohorts at both dose levels, demon …
BACKGROUND AND OBJECTIVE: Palovarotene is an oral, selective retinoic acid receptor gamma agonist under investigation for fibrodyspla …
A Randomised Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Palovarotene Ophthalmic Solution.
Foster WJ, Strahs AL, Small KW, Roach JM. Foster WJ, et al. Drugs R D. 2023 Mar;23(1):43-53. doi: 10.1007/s40268-022-00410-6. Epub 2022 Dec 21. Drugs R D. 2023. PMID: 36542308 Free PMC article. Clinical Trial.
BACKGROUND AND OBJECTIVE: Palovarotene, a selective retinoic acid receptor gamma agonist, is under investigation for the treatment of dry eye disease. This study aimed to determine the ocular and systemic safety, tolerability and pharmacokinetics of palovarotene oph …
BACKGROUND AND OBJECTIVE: Palovarotene, a selective retinoic acid receptor gamma agonist, is under investigation for the treatment of …
Randomised controlled trial for emphysema with a selective agonist of the γ-type retinoic acid receptor.
Stolk J, Stockley RA, Stoel BC, Cooper BG, Piitulainen E, Seersholm N, Chapman KR, Burdon JG, Decramer M, Abboud RT, Mannes GP, Wouters EF, Garrett JE, Barros-Tizon JC, Russi EW, Lomas DA, MacNee WA, Rames A. Stolk J, et al. Eur Respir J. 2012 Aug;40(2):306-12. doi: 10.1183/09031936.00161911. Epub 2012 Jan 26. Eur Respir J. 2012. PMID: 22282548 Free article. Clinical Trial.
Palovarotene is an oral gamma-selective retinoid agonist. In animal emphysema models, palovarotene reduced inflammation, promoted structural repair and functional improvement. ...We randomly assigned 133 and 129 patients to placebo or palovarotene, respective
Palovarotene is an oral gamma-selective retinoid agonist. In animal emphysema models, palovarotene reduced inflammation, promo
Retinoid treatment of Emphysema in Patients on the Alpha-1 International Registry. The REPAIR study: study design, methodology and quality control of study assessments.
Stolk J, Cooper BG, Stoel B, Rames A, Rutman O, Soliman S, Stockley R. Stolk J, et al. Ther Adv Respir Dis. 2010 Dec;4(6):319-32. doi: 10.1177/1753465810379617. Epub 2010 Oct 6. Ther Adv Respir Dis. 2010. PMID: 20926506 Free article. Clinical Trial.
The REPAIR study (Retinoid treatment of Emphysema in Patients on the Alpha-1 International Registry) is the first proof-of-concept study of a new potential disease-modifying drug, Palovarotene, an orally active, gamma selective retinoid agonist in patients with emphysema s …
The REPAIR study (Retinoid treatment of Emphysema in Patients on the Alpha-1 International Registry) is the first proof-of-concept study of …